"We have a once in a generation opportunity and responsibility to use this transformative modality to change patients’ lives.
Kymera's people and our culture are our secret, and I'm committed to nurturing our truth seeking culture, which has been key to our success.”

Nello Mainolfi, Ph.D.

Founder, President & CEO

Nello is Founder, President, and Chief Executive Officer of Kymera Therapeutics. Under his leadership, Kymera has advanced a novel modality and built a pipeline of multiple clinical stage, first-in-class degrader programs across a variety of indications; developed a best-in-class drug discovery platform; raised more than $1 billion in capital and formed strategic collaborations with major biopharmaceutical companies. Nello began his career at Novartis, leading cross-functional teams that identified several novel investigational medicines including the first-in-class, FDA approved, factor B inhibitor iptacopan. Before founding Kymera, Nello was an Entrepreneur in Residence at Atlas Venture. Nello studied at Imperial College, University of London and The Scripps Research Institute in California and has authored more than 100 publications and patents. He is passionate about helping teams achieve what has not been done before and scaling Kymera into a leading global biopharma company.